SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its...
News
Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Confere… […]
News
Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to presen… […]
News
Satsuma Pharmaceuticals Appoints Rob Janosky?as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janosky to the newly created position of Chief Commercial… […]
